WE CLAIM:

1. A benzisothiazole-3(2H)-one compound of formula (I)



(I)

wherein;

R_1 is the group $(C_5\text{-}C_{12})$alkyl, $(C_4\text{-}C_{12})$haloalkyl, $(C_4\text{-}C_{12})$alkenyl, $(C_4\text{-}C_{12})$alkynyl, $(C_1\text{-}C_8)$alkylcycloalkyl, $(C_3\text{-}C_8)$cycloalkyl, $(C_1\text{-}C_{12})$alkylheterocyclic radical or aryl wherein the aryl or heterocyclkic group is optionally substituted with one 1 to 3 groups independently selected from $(C_1\text{-}C_{12})$alkyl, $(C_2\text{-}C_{12})$alkenyl, $(C_1\text{-}C_{12})$alkoxy, (C1-C8)alkylcycloalkyl, halo, and $(C_1\text{-}C_{12})$haloalkyl;

R_2 is hydrogen;

R_3, R_4, R_5, and R_6, are each independently selected from hydrogen, $(C_2\text{-}C_{12})$alkyl, $(C_1\text{-}C_{12})$haloalkyl, $(C_1\text{-}C_{12})$alkoxyalkyl, $(C_1\text{-}C_{10})$thioalkyl, hydroxy, $(C_2\text{-}C_{12})$alkenyl, $(C_2\text{-}C_{12})$alkynyl, $(C_1\text{-}C_{12})$alkylaryl, $(C_1\text{-}C_{12})$alkylcycloalkyl, $(C_1\text{-}C_{12})$alkylheterocyclic, $C(O)C_1\text{-}C_6$ alkyl, $C(O)OC_1\text{-}C_6$alkyl, phenyl or aryl; wherein each of alkyl, alkenyl, phenyl or aryl groups may be optionally substituted with one to three substitutents selected from halo, amino, halo, $C_1\text{-}C_6$ alkyl, $(C_2\text{-}C_6)$alkennyl, $(C_1\text{-}C_6)$haloalkyl; or a pharmaceutically acceptable salt, solvate or isomer thereof.

2. Use of a compound of a benzisothiazole-3(2H)-one compound of formula (I), or a pharmaceutically acceptable salt, solvate or prodrug thereof:



(I)

wherein;

R_1 is the group $(C_5\text{-}C_{12})$alkyl, $(C_4\text{-}C_{12})$haloalkyl, $(C_4\text{-}C_{12})$alkenyl, $(C_4\text{-}C_{12})$alkynyl, $(C_1\text{-}C_8)$alkylcycloalkyl, $(C_3\text{-}C_8)$cycloalkyl, $(C_1\text{-}C_{12})$alkylheterocyclic radical or aryl wherein the aryl or heterocyclkic group is optionally substituted with one 1 to 3 groups independently selected from $(C_1\text{-}C_{12})$alkyl, $(C_2\text{-}C_{12})$alkenyl, $(C_1\text{-}C_{12})$alkoxy, $(C_1\text{-}C_8)$alkylcycloalkyl, halo, and $(C_1\text{-}C_{12})$haloalkyl;

R_2 is hydrogen;

R_3, R_4, R_5, and R_6, are each independently selected from hydrogen, $(C_2\text{-}C_{12})$alkyl, $(C_1\text{-}C_{12})$haloalkyl, $(C_1\text{-}C_{12})$alkoxyalkyl, $(C_1\text{-}C_{10})$thioalkyl, hydroxy, $(C_2\text{-}C_{12})$alkenyl, $(C_2\text{-}C_{12})$alkynyl, $(C_1\text{-}C_{12})$alkylaryl, $(C_1\text{-}C_{12})$alkylcycloalkyl, $(C_1\text{-}C_{12})$alkylheterocyclic, $C(O)C_1\text{-}C_6$ alkyl, $C(O)OC_1\text{-}C_6$alkyl, phenyl or aryl; wherein each of alkyl, alkenyl, phenyl or aryl groups may be optionally substituted with one to three substitutents selected from halo, amino, halo, $C_1\text{-}C_6$ alkyl, $(C_2\text{-}C_6)$alkennyl, $(C_1\text{-}C_6)$haloalkyl; or a pharmaceutically acceptable salt, solvate or isomer thereof, for the treatment and/or prevention of hepatic lipase and/or endothelial lipase mediated activities.

3. A compound according to Claim 1 wherein R_1, is $(C_5\text{-}C_8)$alkyl, $(C_4\text{-}C_6)$alkenyl, -O-$(C_1\text{-}C_3$ alkyl), $(C_3\text{-}C_4)$alkylcycloalkyl, $-CF_3$, or aryl.

4. A compound according to Claim 1 wherein R_1, is benzyl substituted with 0, 1 or 2 substitutents selected from $(C_1\text{-}C_6)$alkyl, $(C_2\text{-}C_4)$alkenyl, -O-$(C_1\text{-}C_3$ alkyl), $(C_1\text{-}C_4)$alkylcycloalkyl, and $-CF_3$,

5. A compound of Claim 1 wherein R_3, R_4, R_5 and R_6 are independently selected from the group consisting of $(C_1\text{-}C_4)$alkyl, $(C_2\text{-}C_4)$alkenyl, -O-$(C_1\text{-}C_3$ alkyl), -S-$(C_1\text{-}C_3$ alkyl), $(C_5\text{-}C_{12})$cycloalkyl, COOH, C(O)$(C_1\text{-}C_3$ alkyl), C(O)O$(C_1\text{-}C_3$ alkyl), $-CF_3$, and halo.

6. The compound of Claim 1 wherein R_5 is the group represented by COOH, C(O)$(C_1\text{-}C_3$ alkyl), C(O)O$(C_1\text{-}C_3$ alkyl), chloro, bromo or CF_3.

7. A compound of formula (I) selected from the group consisting of:
3-Oxo-3*H*-benzo[*d*]isothiazole-2-carboxylic acid ethylamide;
3-Oxo-3*H*-benzo[*d*]isothiazole-2-carboxylic acid propylamide;
3-Oxo-3*H*-benzo[*d*]isothiazole-2-carboxylic acid allylamide;
3-Oxo-3*H*-benzo[*d*]isothiazole-2-carboxylic acid pentylamide;
3-Oxo-3*H*-benzo[*d*]isothiazole-2-carboxylic acid hexylamide;
3-Oxo-3*H*-benzo[*d*]isothiazole-2-carboxylic acid (5-methyl-hexyl)-amide;
3-Oxo-3*H*-benzo[*d*]isothiazole-2-carboxylic acid dodecylamide;
3-Oxo-3*H*-benzo[*d*]isothiazole-2-carboxylic acid cyclohexylamide;
3-Oxo-3*H*-benzo[*d*]isothiazole-2-carboxylic acid benzylamide;
3-Oxo-3*H*-benzo[*d*]isothiazole-2-carboxylic acid 2-methyl-benzylamide;
3-Oxo-3*H*-benzo[*d*]isothiazole-2-carboxylic acid 3-methyl-benzylamide;
3-Oxo-3*H*-benzo[*d*]isothiazole-2-carboxylic acid 4-methyl-benzylamide;
3-Oxo-3*H*-benzo[*d*]isothiazole-2-carboxylic acid 2-ethyl-6-methyl-benzylamide;
3-Oxo-3*H*-benzo[*d*]isothiazole-2-carboxylic acid 2-isopropyl-6-methyl-benzylamide;
3-Oxo-3*H*-benzo[*d*]isothiazole-2-carboxylic acid phenethylamide;
3-Oxo-3*H*-benzo[*d*]isothiazole-2-carboxylic acid (2-thiophen-2-yl-ethyl)-amide;
3-Oxo-3*H*-benzo[*d*]isothiazole-2-carboxylic acid (3-phenyl-propyl)-amide;
3-Oxo-3*H*-benzo[*d*]isothiazole-2-carboxylic acid (4-phenyl-butyl)-amide;
3-Oxo-3*H*-benzo[*d*]isothiazole-2-carboxylic acid (4-cyclohexyl-butyl)-amide;
5-Methyl-3-oxo-3*H*-benzo[*d*]isothiazole-2-carboxylic acid butylamide;

6-Chloro-3-oxo-3*H*-benzo[*d*]isothiazole-2-carboxylic acid propylamide;

6-Chloro-3-oxo-3*H*-benzo[*d*]isothiazole-2-carboxylic acid isopropylamide;

6-Chloro-3-oxo-3*H*-benzo[*d*]isothiazole-2-carboxylic acid butylamide;

6-Chloro-3-oxo-3*H*-benzo[*d*]isothiazole-2-carboxylic acid hexylamide;

6-Chloro-3-oxo-3*H*-benzo[*d*]isothiazole-2-carboxylic acid cyclohexylamide; and

6-Chloro-3-oxo-3*H*-benzo[*d*]isothiazole-2-carboxylic acid benzylamide.

8. A benzisothiazole-3(2H)-one compound represented by the formulae (C1), (C2), (C3), or (C4):



(C1),



(C2),



(C3),



(C4).

9. A pharmaceutical formulation comprising a benzisothiazole-3(2H)-one compound of formula I together with a pharmaceutically acceptable carrier or diluent.

10. A method of inhibiting hepatic lipase and/or endothelial lipase activity using a therapeutically effective amount of benzisothiazole-3(2H)-one compound of formula I.

11. A method of treating a mammal to alleviate the pathological effects of elevated hepatic lipase and/or endothelial lipase activity; comprising administering to said mammal a therapeutically effective amount of a benzisothiazole-3(2H)-one compound according to Claim 1.

12. A pharmaceutical formulation containing a therapeutically effective amount of the compound of formula 1 useful for the treatment and/or amelioration of the effect of elevated hepatic lipase and/or endothelial lipase activity.

13. Use of a compound of formula I ofr the treatment and /or prevention of low HDL levels associated with elelvated hepatic lipase and/or endothelial lipase activity

14. Use of a pharmaceutical composition comprising a therapeutically effective amount of a hepatic lipase and/or endothelial lipase inhibitor compound according to Claim 1 and mixtures thereof for the manufacture of a medicament for the treatment of disease mediated by hepatic lipase and/or endothelial lipase activity.

15. Use of a benzisothiazole-3(2H)-one compound of formula I for the manufacture of a medicament for the treatment or prevention of hepatic lipase and/or endothelial lipase mediated disease comprising administering a therapeutically effective amount of a benzisothiazole-3(2H)-one compound of formula (I), or a

pharmaceutically acceptable salt, solvate or prodrug thereof: